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Objective: There have been few prospective, multicenter studies investigating
the natural history of type 1 diabetes (T1D) from the time of diagnosis. The
objective of this report from the Pediatric Diabetes Consortium (PDC) T1D
New Onset (NeOn) study was to assess the natural history and clinical
outcomes in children during the first year after diagnosis of T1D.
Research design and methods: Clinical measures from the first year following
diagnosis were analyzed for 857 participants (mean age 9.1 yr, 51% female,
66% non-Hispanic White) not participating in an intervention study who had
a HbA1c result at 12months.
Results Mean HbA1c ± SD was 102± 25mmol/mol (11.4± 2.3%) at
diagnosis, 55± 12mmol/mol (7.2± 1.1%) at 3months, 56± 15mmol/mol
(7.3± 1.3%) at 6months and 62± 16mmol/mol (7.8± 1.5%) at 12months
from diagnosis. A severe hypoglycemic (SH) event occurred in 31 (4%)
participants (44 events, 5.2 events per 100 person-years). Diabetic ketoacidosis
(DKA) not including diagnosis occurred in 10 (1%) participants (13 events, 1.5
events per 100 person-years).
Conclusions: After onset of T1D, mean HbA1c reaches its nadir at
3–6months with a gradual increase through 12months. SH and DKA are
uncommon but still occur during the first year with T1D. Data from large
cohorts, such as the PDC T1D NeOn study, provide important insights into
the course of T1D during the first year following diagnosis, which will help to
inform the development of models to target future interventions.
Eda Cengiza, Crystal G
Connorb, Katrina J Ruedyb,
Roy W Beckb, Craig
Kollmanb, Georgeanna J
Klingensmithc, William V
Tamborlanea, Joyce M
Leed,e, Michael J Hallerf
for the Pediatric Diabetes
Consortium†
aDepartment of Pediatric
Endocrinology, Yale University, New
Haven, CT 06520, USA; bJaeb Center
for Health Research, Tampa, FL
33647, USA; cDepartment of
Pediatrics, Barbara Davis Center for
Childhood Diabetes, University of
Colorado, Aurora, CO 80045, USA;
dDepartment of Pediatric
Endocrinology, Mott Children’s
Hospital, University of Michigan, Ann
Arbor, MI 48109, USA; eChild Health
Evaluation and Research Unit,
University of Michigan, Ann Arbor, MI
48109, USA; and fDepartment of
Pediatric Endocrinology, University of
Florida, Gainesville, FL 32605, USA
†Members of the Study Group are
listed in the Appendix.
Key words: children – diabetes –
HbA1c or glycemic control
Corresponding author:
Katrina J Ruedy, MSPH,
Jaeb Center for Health Research,
15310 Amberly Drive,
Suite 350,
Tampa, FL 33647, USA.
Tel: (813) 975-8690;
fax: (888) 795-2858;
e-mail: pdc@jaeb.org
Submitted 1 March 2013. Accepted
for publication 28 June 2013
287
Cengiz et al.
The Diabetes Control and Complications Trial
(DCCT) and its follow-up Epidemiology of Diabetes
Interventions and Complications (EDIC) study clearly
demonstrated that patients with type 1 diabetes (T1D)
should aim for blood glucose and A1c levels as close to
normal as possible and as early in the course of T1D
as possible to prevent or delay the vascular and neuro-
pathic complications of the disease (1–4). While these
goals of therapy were particularly difficult to achieve in
youth with T1D in the DCCT (2), the introduction of
rapid and long acting insulin analogs, improvements
in insulin pump technology and the development of
continuous glucose monitoring (CGM) devices have
provided clinicianswith bettermethods to achieve strict
glycemic control. Despite these advances, treatment
outcomes recently reported by leading pediatric dia-
betes treatment centers involved in the T1D Exchange
Clinic Registry demonstrated that too many youth
with established T1D fail to achieve target A1c levels
and the rates of severe hypoglycemia (SH) and diabetic
ketoacidosis (DKA) remain unacceptably high (5).
The early honeymoon period of T1D is the one
phase of the disease where a substantial proportion
of youth with new-onset T1D are able to achieve
excellent glucose control with minimal risks of acute
complications. Moreover, it has long been recognized
thatmaintenance of strictmetabolic control will help to
prolong the honeymoon period by slowing the loss of
residual endogenous insulin secretion (1).Nevertheless,
there have been few recent studies in clinical practice
settings that have evaluated the impact of therapy
of youth with new-onset T1D on the outcomes of
treatment during the early phases of the disease. To
fill this void, the Pediatric Diabetes Consortium (PDC)
T1D New Onset (NeOn) Study was undertaken by
seven pediatric diabetes centers in the USA caring for
children and adolescents with T1D. This article reports
on the major clinical outcomes of this cohort during
the first year following diagnosis.
Study design and methods
Patients
The PDC enrolled 1052 patients diagnosed with T1D
based on American Diabetes Association criteria (6)
between July 2009 and April 2011. The protocol was
approved by the Institutional Review Board (IRB)
at each of the seven participating centers. Informed
consentwas obtained fromparticipants 18 yr of age and
from parents of those less than 18 yr of age. Assent was
obtained from participants <18 yr of age as required
by local IRB regulations. To be eligible for enrollment
in the study, patients had to be <19 yr of age and
managed at one of the seven participating PDC centers
within 3months of diagnosis. A detailed description of
PDC and the design of the study have been published
previously (7). The analyses herein included 857 of
the 1052 PDC participants: 163 were not included
because a 1 yr HbA1c measurement (319–455 d from
diagnosis) was not available and 32 were excluded due
to participation in an intervention study.
Data collection
Demographic, socioeconomic and clinical character-
istics, laboratory data, hospitalizations, SH events,
and DKA events were collected from medical records
and from interviews with the participant and/or par-
ent at onset and at 1, 3, 6, 9, and 12months from
diagnosis. Follow-up visits were completed per usual
care and all visits during the first year post-diagnosis
were entered in the standardized electronic case report
forms for the study. SH was defined as events that
led to alterations in consciousness that were so severe
that they required the assistance of another person to
administer carbohydrate, glucagon, or other resusci-
tative actions. For those developmentally too young
to independently recognize and treat hypoglycemia,
hypoglycemia was considered severe if there were asso-
ciated signs or symptomsof neuroglycopenia, including
temporary impairment of cognition; incoherent, dis-
oriented, and/or combative behavior; seizure; or coma.
DKA was defined according to DCCT criteria (1) of
pH <7.3 or HCO3 <15mEq/L and treatment in a
healthcare facility. SH and DKA events were included
in the analysis if they occurred between 7 and 365 d
from diagnosis. Body mass index (BMI) was computed
from the closest height and weight measured by the
healthcare provider within 14 d of diagnosis. BMI per-
centile and standard deviation score for age and gender
were calculated using the 2000 CDC (Centers for Dis-
ease Control and Prevention) population growth chart
data (8).
The insulin dose adjusted HbA1c (IDAA1c) was
defined as HbA1c %+ [4 × insulin dose (units per kg
per 24 h)] (9). Two separate criteriawere used to assess a
partial remission at each time point mentioned above:
(1) IDAA1c ≤9.0% and (2) HbA1c <53mmol/mol
(7.0%) and total daily insulin dose <0.5 units per kg
per day (10, 11).
Statistical analyses
The cumulative incidences of SH, DKA, emergency
room (ER) visits and hospitalizations were calculated
with the Kaplan–Meier estimator. Event rates were
determined as the total number of events divided by
the total amount of follow-up time scaled to events
per 100 person-years. Follow-up times were based on
the last visit within 365 d from diagnosis for each
participant. Cox regression was used to determine the
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association of the following baseline factors with SH
events in the first year: age, gender, race/ethnicity,
health insurance status, parental education, family
income, family structure, and DKA at diagnosis. A
baseline multivariate model was constructed using
stepwise selection with p-values <0.10 required to be
included in the model. Owing to multiple comparisons,
only factors with p-values <0.01 were considered
statistically significant, although factors with p-values
<0.10were included in themodel to adjust for potential
confounding. All analyses were performed using SAS
version 9.3 (SAS Institute, Cary, NC, USA).
Results
The 857 participants included in the analysis had a
mean age of 9.1 yr (range 0.7–18.8 yr); 51% were
female; 66% were non-Hispanic White, 21% were
Hispanic, and 7% were non-Hispanic Black. The
majority of participants had health insurance, at least
some college for parent education and a family income
above $50 000. At diagnosis, 11% of the participants
were overweight (85 to <95% BMI percentile) and 9%
obese (≥95% BMI percentile) and 33% presented in
DKA (Table 1).
Mean HbA1c± SD was 102± 25mmol/mol
(11.4± 2.3%) at diagnosis and dropped to
74± 16mmol/mol (8.9± 1.5%) 1 month later. HbA1c
values continued to fall reaching a minimum mean
value of 55± 12mmol/mol (7.2± 1.1%) at 3months
and 56± 15mmol/mol (7.3± 1.3%) at 6months,
and then rising to 62± 16mmol/mol (7.8± 1.5%)
12months from diagnosis (Table 2). HbA1c was
≤53mmol/mol (7.0%) for 33% of participants at
12months. The IDAA1c was 11.2± 2.1% 1 month
from diagnosis, dropped to its lowest value at 3 and
6months (mean 9.3%) and then rose to 10.4± 2.2%
at 12months. HbA1c and IDAA1c trajectories were
similar when restricting analysis to participants with
data at all six time points (HbA1c: n= 216; IDAA1c:
n= 86; data not shown). More participants met the
criterion for partial remission defined by IDAA1c
≤9% (24% at 12months) than the alternate criterion of
HbA1c <53mmol/mol (7.0%) and insulin dose <0.5
u/kg/d (12% at 12months; Table 2).
Participants initiated insulin injections at diagnosis
with either multiple daily injections (55%), or a fixed
dose (45%) where daily insulin doses remain the same
with consistent amounts of carbohydrate eaten at each
meal and an added insulin amount for adjustment
for glucose value. By 12months from onset, 29% of
participants were using an insulin pump. Insulin dose
was relatively steady over the first year of T1D and
did not vary meaningfully by age or gender. Only
1% of participants were using a CGM at 12months.
The median number of self-monitored blood glucose
Table 1. Participant characteristics at diagnosis (N = 857*)
N %
Age at diagnosis
<5 yr 165 19
5 to <12 yr 481 56
12 to <19 yr 211 25
Mean ± SD 9.1 ± 4.1
Range 0.7–18.8
Gender
Female 436 51
Race/Ethnicity
White (non-Hispanic) 549 66
Hispanic or Latino 175 21
Black/African
American
59 7
Other/multiple race 54 6
Health insurance
Private 576 68
CHP or other Gov’t
sponsored
235 28
Military 16 2
None 15 2
Parent education
High school or less 225 32
AA 103 15
BS/BA 204 29
MS/MA/Professional
Degree
162 23
Family income
<$25 000 75 13
$25 000–$49 999 111 19
$50 000–$74 999 97 17
$75 000–$99 999 81 14
≥$100 000 213 37
BMI Percentile
<85% 401 81
85 to <95% 52 10
≥95% 43 9
DKA at diagnosis 275 33
HbA1c
37 to <86 mmol/
mol (5.5 to <10%)
226 28
86 to <119 mmol/
mol (10 to <13%)
368 45
≥119 mmol/
mol (≥13%)
224 27
Mean ± SD 102 ± 25 mmol/mol (11.4 ± 2.3%)
Range 37–180 mmol/mol (5.5–18.6%)
*Number of participants with missing data: race/ethnicity
(20), health insurance (15), parent education (163), family
income (280), body mass index (BMI) percentile (361), dia-
betic ketoacidosis (DKA) at diagnosis (27) and HbA1c (39).
(SMBG) tests per day (5 tests/d) remained consistent
throughout the first year of T1D. BMI percentiles
increased fromdiagnosis to 1month and then remained
fairly stable for the remainder of the year (Table 3).
During the first year of T1D, SH occurred in 31 (4%)
participants (44 events) for a rate of 5.2 events per 100
person-years; seizure or loss of consciousness occurred
in 17 (39%) of the 44 events. DKA occurred in 10 (1%)
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Table 2. HbA1c and insulin dose adjusted HbA1c (IDAA1c)
Time from diagnosis
Baseline
(N = 818)
1 month
(N = 551)
3 month
(N = 683)
6 month
(N = 705)
9 month
(N = 673)
12 month
(N = 857)
HbA1c
Mean ± SD (mmol/mol) 102 ± 25 74 ± 16 55 ± 12 56 ± 15 59 ± 15 62 ± 16
Mean ± SD (%) 11.4 ± 2.3 8.9 ± 1.5 7.2 ± 1.1 7.3 ± 1.3 7.6 ± 1.4 7.8 ± 1.5
≤53 mmol/mol (7.0%) 3% 7% 50% 50% 39% 33%
IDAA1c N/A N= 479 N=562 N=588 N=547 N=732
Mean ± SD (%) 11.2 ± 2.1 9.3 ± 1.8 9.3 ± 2.0 9.9 ± 2.1 10.4 ± 2.2
IDAA1c ≤9.0% 11% 51% 50% 35% 24%
HbA1c <53 mmol/mol (7.0%)
and insulin <0.5 u/kg/d
4% 27% 28% 16% 12%
Table 3. Insulin regimen, dosage and continuous glucose monitoring (CGM) use
1 month 3 month 6 month 9 month 12 month
Insulin delivery N=618 N=687 N=713 N=673 N=855
Pump 3 (<1%) 58 (8%) 118 (17%) 171 (25%) 282 (33%)
Injections (fixed dose) 255 (41%) 153 (22%) 123 (17%) 91 (14%) 97 (11%)
Injections (MDI) 360 (58%) 476 (69%) 472 (66%) 411 (61%) 476 (56%)
N=587 N= 655 N=679 N=640 N=812
CGM users 1 (<1%) 1 (<1%) 7 (1%) 5 (1%) 12 (1%)
CGM and pump users 0 0 2 (<1%) 3 (<1%) 11 (1%)
Self blood glucose monitoring
(# tests/d)
N=406 N= 425 N=436 N=404 N=497
Median (25th, 75th percentile) 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 6)
Insulin dosage (u/kg/d) N=500 N= 562 N=592 N=552 N=733
Mean (SD) 0.6 (0.3) 0.5 (0.3) 0.5 (0.3) 0.6 (0.3) 0.7 (0.3)
Median (25th, 75th percentile) 0.5 (0.4, 0.7) 0.5 (0.3, 0.6) 0.5 (0.3, 0.7) 0.5 (0.4, 0.7) 0.6 (0.5, 0.8)
Mean insulin dosage (u/kg/d) by age
and gender
<5 yr
Female (N = 71) 0.4 0.5 0.5 0.7 0.7
Male (N = 89) 0.5 0.5 0.5 0.6 0.6
5 to <12 yr
Female (N = 262) 0.6 0.5 0.5 0.6 0.7
Male (N = 212) 0.5 0.5 0.5 0.5 0.6
12 to <19 yr
Female (N = 94) 0.7 0.6 0.6 0.6 0.7
Male (N = 115) 0.7 0.6 0.6 0.6 0.7
BMI percentile
<85% 370 (70%) 457 (71%) 485 (72%) 466 (73%) 605 (72%)
85 to <95% 92 (17%) 104 (16%) 116 (17%) 108 (17%) 130 (16%)
≥95% 68 (13%) 80 (12%) 75 (11%) 68 (11%) 103 (12%)
BMI, body mass index.
participants (13 events) during the first year of T1D
not including episodes at presentation for a rate of 1.5
events per 100 person-years. Table 4 shows the SH
and DKA rates according to age and Fig. 1 shows the
frequencies during the first year. After adjusting for
clinical site, SH events were more likely with younger
age (7% for those <5 yr old, 3% for 5–11 yr olds,
and 1% for 12–17 yr olds; p-value= 0.002) and with a
history of DKA at diagnosis (6 vs. 2%; p-value= 0.01).
For reasons other than SH or DKA, there were 96
trips to the ER by 79 (9%) and 29 hospitalizations
unrelated to SH or DKA for 26 (3%) participants. The
frequencies for these are also shown in Fig. 1.
Discussion
The PDC T1D NeOn study is comprised of a large
cohort of children and adolescents in the USA
followed from the onset of T1D. Compared with the
SEARCHforDiabetes inYouthStudy, the percentages
of Hispanic and African-American participants in
the NeOn cohort are slightly higher and gender
distributions are similar (12). Mean HbA1c values at
diagnosis were similar to those reported in other studies
(13–15). The majority of patients were from well-
educated, non-Hispanic white families with relatively
high socioeconomic status. The 19% prevalence of
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Table 4. Severe hypoglycemic*,‡(SH), diabetic ketoacidosis‡
(DKA), emergency room (ER) visits†, and hospital admissions†
(N = 857)
Rate
(total # events)
SH Events per 100
person-years
5.2 (44)
SH Rate by Age at Diagnosis
<5 yr 10.5 (17)
5 to <12 yr 4.0 (19)
12 to <19 yr 3.8 (8)
SH impairment by age at
diagnosis
Frequency (% of SH events)
Seizure/ Loss Conscious 17 (39%)
<5 yr 10 (59%)
5 to <12 yr 7 (37%)
12 to <19 yr 0
Required assistance§ 25 (57%)
<5 yr 6 (35%)
5 to <12 yr 11 (58%)
12 to <19 yr 8 (100%)
SH Treatment¶
Glucagon given 19 (43%)
ER visit 18 (41%)
Hospital admission 2 (5%)
Ambulance 9 (20%)
Emergency medical
technician assist
9 (20%)
SH outcome
Fully recovered 44 (100%)
Rate (total # events)
DKA events per 100
person-years
1.5 (13)
DKA rate by age at diagnosis
<5 yr 2.5 (4)
5 to <12 yr 1.1 (5)
12 to <19 yr 1.9 (4)
# Events/Patients
ER visits 96/79
Hospital admissions 29/26
Floor‖only 20/19
ICU and floor‖ 6/4
ICU only 3/3
*A SH event is defined as a hypoglycemic event
that required the assistance of another person due to
altered consciousness to actively administer carbohydrate,
glucagon, or other resuscitative actions. Multiple episodes
of SH events on the same day counted as one episode and
any episode on a separate calendar date was counted as a
new event.
†ER visits and Hospital admissions due to reasons other
than SH or DKA.
‡Twenty-four participants had one SH event, five
participants had two SH events, one participant had four SH
events and one participant had six SH events. All 44 events
occurred when participant was not wearing a continuous
glucose monitoring (CGM) sensor or had unknown status of
sensor wearing. Seven participants had one DKA event and
three participants had two DKA events.
§Required assistance without seizure or loss conscious.
¶Same participant can have more than one treatment.
‖‘Floor’ is a non-ICU inpatient admission.
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Fig. 1. Cumulative incidences of severe hypoglycemia (SH), diabetic
ketoacidosis (DKA), ER visits, and Hospital admissions within the
first year of T1D (N= 857). Hospital admissions and ER visits due
to reasons other than SH or DKA.
overweight and obesity at diagnosis indicates that the
pediatric population with T1D is not immune to the
obesity epidemic.
The temporal changes in total daily insulin doses
and HbA1c levels over the first year of treatment of
T1D provide insights regarding the partial remission
phase of diabetes as it is currently being observed in
clinical practice settings. The lowest mean total daily
insulin doses were rapidly achieved by 1–3months of
treatment, reflecting the start of the remission phase
during the first few months of treatment, whereas
reductions in HbA1c values lagged behind and did
not reach nadir levels until 3–6months. Mean HbA1c
levels subsequently increased at 9 and 12months while
total daily insulin doses changed little suggesting that
as the honeymoon phase was waning, insufficient
attention was paid to the need to increase insulin doses.
Nevertheless, the mean HbA1c of 62mmol/mol (7.8%)
in the T1D NeOn cohort compares favorably to mean
HbA1c levels between 64 and 75mmol/mol (8.0–9.0%)
at 1 yr post-diagnosis that have been reported in other
pediatric cohorts (16–19). The proportion of patients
who switched to pump therapy rose sharply during the
second 6 months of treatment.
A variety of metrics have been used by clinicians as
rules of thumb to identify patients in the honeymoon
phase, including HbA1c levels <53mmol/mol (7.0%),
total daily insulin <0.5 u/kg/d or, more commonly,
the combination of both (10, 11). A retrospective
chart review of a smaller group of subjects from a
pediatric diabetes center in the USA reported similar
mean HbA1c levels at 6months followed by higher
values at 9 and 12months as compared to our data.
While the percent of subjects in partial remission
at 6months after diagnosis was comparable to our
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group, it was lower at 12months despite the fact that
partial remission was defined as total daily insulin
dose< 0.5 u/kg body weight/d with a relatively higher
HbA1C of <64mmol/mol (8%) (17). More recently,
Mortensen et al. (9) described and validated a new
metric that they termed the IDAA1c defined as equal
to the HbA1c level+ 4 × total daily insulin dose
(u/kg/d). They demonstrated that an IDAA1c value
≤9.0 corresponds to a predicted stimulated C-peptide
>300 pmol/L. Rather than using arbitrary cut points
for HbA1c and daily insulin dose, IDAA1c is a
continuous variable that accounts for patients who
might have mild elevations in HbA1c levels above
53mmol/mol (7.0%) in the face of very low total
daily insulin doses. Thus it is noteworthy that the
percentage of participants in remission at 6 (50 vs.
44%) and 12months (24 vs. 18%) in our study is
comparable with Mortensen et al.’s (9) findings and
that IDAA1c identified nearly twice asmany patients in
partial remission than the older combination cut point
method (10, 11).
With respect to glucose monitoring, self-monitoring
blood glucose measurements averaged 4–6 tests/d
during the entire year of study. CGM was prescribed
infrequently during the first year. Approximately half
of the SH events occurred during the first half of
the year when insulin sensitivity has been shown
to increase (20, 21), while DKA events clustered in
the second half of the year when HbA1c levels were
rising.
The NeOn Study data provide relevant information
to inform pediatric clinical care of T1D. The findings
indicate that the 6-month visit may be an ideal time
to proactively counsel families that they will need to
increase their vigilance in recognizing glucose trends
and in increasing insulin doses over the next few
months to compensate for waning of endogenous
insulin secretion. The 6- and 9-month visits may
also be good times to review sick day management
rules and protocols to prevent ketoacidosis. The
findings of this study can also help inform the
design and sample size estimates of future beta-cell
preservation trials for new-onset patients by providing
data on the outcomes that might be expected in
the control group that will receive standard diabetes
management.
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